|
Dr. Lebowitz joined the Company in 2000 as a Staff Scientist and was then promoted to Director, Parkinsonšs Disease Program and Project Leader, HAAH Oncology Therapeutics in early 2002. He was promoted to Director of Research in 2004.
Prior to joining Panacea, Dr. Lebowitz was a research scientist at Proteinix Corporation in Gaithersburg, Maryland where he was involved in the development of compounds for the control of ubiquitin-dependent protein degradation. He has published numerous articles and abstracts in the fields of enzymology, cellular immunology, cancer, and neurodegenerative disease. He is also an inventor on several patents and has served as a principal investigator on several NIH-funded SBIR grants.
Dr. Lebowitz received his Ph.D. from the Johns Hopkins University School of Medicine in Biochemistry, Cellular, and Molecular Biology. Subsequently, he completed a three year fellowship in immunology in the Department of Pathology, Division of Immunopathology also at the JHU School of Medicine. Dr. Lebowitz is also currently an adjunct Lecturer in the Advanced Academic Program in Biotechnology at the Krieger School of Arts and Sciences, JHU. | 